Understanding how some advanced cancer patients benefit long-term from immune therapies
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
This study is looking at patients with advanced cancer who have had lasting positive results from certain immune treatments, to learn more about what helps them live longer and how to support their needs better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10929397 on NIH RePORTER |
What this research studies
This research investigates patients with advanced cancer who have experienced long-lasting benefits from immune checkpoint inhibitors (ICIs). It involves two groups: a large retrospective analysis of over 8,800 patients treated with ICIs from 2014 to 2022, and a prospective cohort of about 1,200 patients with durable responses to ICIs, specifically focusing on lung, kidney, and melanoma cancers. The study aims to collect clinical data and patient-reported outcomes to better understand the factors contributing to long-term survival and the ongoing needs of these patients. By following these patients over time, the research seeks to illuminate their symptom trajectories and survivorship challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced lung cancer, kidney cancer, or melanoma who have shown a durable response to immune checkpoint inhibitors.
Not a fit: Patients who have not received immune checkpoint inhibitors or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of how to enhance treatment outcomes for patients with advanced cancer receiving immune therapies.
How similar studies have performed: Previous research has shown promising results in understanding patient responses to immune therapies, making this study a continuation of that successful exploration.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Yao, Song — Roswell Park Cancer Institute Corp
- Study coordinator: Yao, Song
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.